vs
Axe Compute Inc.（AGPU）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
Sanara MedTech Inc.的季度营收约是Axe Compute Inc.的3172.6倍（$27.5M vs $8.7K）。Sanara MedTech Inc.净利率更高（-5.9% vs -1740028.0%，领先1740022.1%）。Sanara MedTech Inc.同比增速更快（4.6% vs -1.3%）。过去两年Axe Compute Inc.的营收复合增速更高（33.6% vs 21.8%）
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
AGPU vs SMTI — 直观对比
营收规模更大
SMTI
是对方的3172.6倍
$8.7K
营收增速更快
SMTI
高出6.0%
-1.3%
净利率更高
SMTI
高出1740022.1%
-1740028.0%
两年增速更快
AGPU
近两年复合增速
21.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $8.7K | $27.5M |
| 净利润 | $-150.9M | $-1.6M |
| 毛利率 | — | 93.2% |
| 营业利润率 | -1990880.1% | 23.5% |
| 净利率 | -1740028.0% | -5.9% |
| 营收同比 | -1.3% | 4.6% |
| 净利润同比 | -6856.6% | 5.3% |
| 每股收益（稀释后） | — | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGPUSMTI
| Q4 25 | $8.7K | $27.5M | ||
| Q3 25 | $3.6K | $26.3M | ||
| Q2 25 | $2.7K | $25.8M | ||
| Q1 25 | $110.3K | $23.4M | ||
| Q4 24 | $8.8K | $26.3M | ||
| Q3 24 | $3.9K | $21.7M | ||
| Q2 24 | $67.3K | $20.2M | ||
| Q1 24 | $4.9K | $18.5M |
净利润AGPUSMTI
| Q4 25 | $-150.9M | $-1.6M | ||
| Q3 25 | $-77.7M | $-30.4M | ||
| Q2 25 | $-2.1M | $-2.0M | ||
| Q1 25 | $-2.4M | $-3.5M | ||
| Q4 24 | $-2.2M | $-1.7M | ||
| Q3 24 | $-3.1M | $-2.9M | ||
| Q2 24 | $-3.2M | $-3.5M | ||
| Q1 24 | $-4.2M | $-1.8M |
毛利率AGPUSMTI
| Q4 25 | — | 93.2% | ||
| Q3 25 | -131.0% | 92.9% | ||
| Q2 25 | -579.4% | 92.5% | ||
| Q1 25 | 59.1% | 92.2% | ||
| Q4 24 | -250.5% | 91.4% | ||
| Q3 24 | -186.1% | 90.8% | ||
| Q2 24 | 79.4% | 90.0% | ||
| Q1 24 | -361.8% | 89.8% |
营业利润率AGPUSMTI
| Q4 25 | -1990880.1% | 23.5% | ||
| Q3 25 | -90654.1% | 11.2% | ||
| Q2 25 | -99174.8% | -0.1% | ||
| Q1 25 | -2073.3% | -8.9% | ||
| Q4 24 | -23848.9% | 18.6% | ||
| Q3 24 | -55296.7% | 3.6% | ||
| Q2 24 | -3664.6% | -14.3% | ||
| Q1 24 | -73734.7% | -8.3% |
净利率AGPUSMTI
| Q4 25 | -1740028.0% | -5.9% | ||
| Q3 25 | -2146264.3% | -115.5% | ||
| Q2 25 | -77198.4% | -7.8% | ||
| Q1 25 | -2214.6% | -15.1% | ||
| Q4 24 | -24676.9% | -6.5% | ||
| Q3 24 | -79208.9% | -13.2% | ||
| Q2 24 | -4730.1% | -17.4% | ||
| Q1 24 | -86843.2% | -9.5% |
每股收益（稀释后）AGPUSMTI
| Q4 25 | — | $-0.32 | ||
| Q3 25 | — | $-3.40 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.41 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $10.8M | $16.6M |
| 总债务越低越好 | — | $46.0M |
| 股东权益账面价值 | $47.7M | $5.9M |
| 总资产 | $52.9M | $72.9M |
| 负债/权益比越低杠杆越低 | — | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资AGPUSMTI
| Q4 25 | $10.8M | $16.6M | ||
| Q3 25 | $181.7K | $14.9M | ||
| Q2 25 | $506.1K | $17.0M | ||
| Q1 25 | $3.1M | $20.7M | ||
| Q4 24 | $611.8K | $15.9M | ||
| Q3 24 | $3.1M | $16.3M | ||
| Q2 24 | $5.3M | $6.2M | ||
| Q1 24 | $5.2M | $2.8M |
总债务AGPUSMTI
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
股东权益AGPUSMTI
| Q4 25 | $47.7M | $5.9M | ||
| Q3 25 | $-77.4M | $6.1M | ||
| Q2 25 | $-1.7M | $35.4M | ||
| Q1 25 | $-145.8K | $36.7M | ||
| Q4 24 | $-202.6K | $39.4M | ||
| Q3 24 | $2.0M | $39.8M | ||
| Q2 24 | $4.1M | $41.7M | ||
| Q1 24 | $4.1M | $43.3M |
总资产AGPUSMTI
| Q4 25 | $52.9M | $72.9M | ||
| Q3 25 | $3.1M | $71.1M | ||
| Q2 25 | $3.4M | $98.8M | ||
| Q1 25 | $5.9M | $96.4M | ||
| Q4 24 | $5.0M | $88.1M | ||
| Q3 24 | $7.5M | $88.5M | ||
| Q2 24 | $10.6M | $73.4M | ||
| Q1 24 | $10.6M | $70.9M |
负债/权益比AGPUSMTI
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-3.9M | $3.9M |
| 自由现金流经营现金流 - 资本支出 | — | $3.9M |
| 自由现金流率自由现金流/营收 | — | 14.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.2M |
8季度趋势，按日历期对齐
经营现金流AGPUSMTI
| Q4 25 | $-3.9M | $3.9M | ||
| Q3 25 | $-1.7M | $2.2M | ||
| Q2 25 | $-3.3M | $2.7M | ||
| Q1 25 | $-985.8K | $-2.0M | ||
| Q4 24 | $-2.1M | $932.0K | ||
| Q3 24 | $-2.5M | $2.1M | ||
| Q2 24 | $-3.2M | $-1.4M | ||
| Q1 24 | $-3.4M | $-1.6M |
自由现金流AGPUSMTI
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | $-2.1M | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | $-3.4M | $-1.7M |
自由现金流率AGPUSMTI
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | -23429.1% | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | -70379.8% | -9.0% |
资本支出强度AGPUSMTI
| Q4 25 | 0.0% | 0.3% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 0.0% | 6.8% | ||
| Q1 25 | 0.0% | 7.4% | ||
| Q4 24 | 73.7% | 0.3% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 62.4% | 0.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AGPU
暂无分部数据
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
